Urethritis is an inflammation of the urethral mucosa that may be caused by various pathogens, most notably C. trachomatis, N. gonorrhea, and M. genitalium. Transmission primarily occurs as a result of unprotected sexual intercourse and it is especially prevalent in young, sexually active men. Patients typically present with urethral discharge, dysuria, and/or itching of the urinary meatus, although asymptomatic infections are common. Diagnostics include urine dipstick (pyuria, positive leukocyte esterase), staining of a urethral sample, and nucleic acid amplification testing of first-void urine. In gonococcal urethritis, Gram staining of the urethral swab demonstrates gram-negative diplococci and patients are treated with ceftriaxone; otherwise patients are treated with azithromycin or doxycycline for nongonococcal urethritis. Evaluation and treatment of all recent sexual partners is necessary to prevent recurrent infections.
- Typically a sexually transmitted infection
- Coinfection is also common
- Most common in young, sexually active men
- Unprotected sexual intercourse
- Multiple sexual partners
- History of other sexually transmitted infections 
- Burning or itching of the urethral meatus
- Urethral discharge: purulent , cloudy, blood-tinged, or clear
- Initial hematuria
- General symptoms (e.g., fever, chills, or myalgia) are uncommon in urethritis and should raise suspicion for complications (see “Complications” below).
Urethritis, especially nongonococcal urethritis, may also be asymptomatic.
- Confirming urethritis
- Identifying the causative pathogen
- Offer to test for HIV, syphilis, and hepatitis B. 
- The initial therapy is usually empiric and, according to prior distinction based on microscopic urethral specimen evaluation, divided into either a GU or NGU regimen. 
- Patients should refrain from sexual activity for 1 week after initiation of therapy.
- All sexual partners from the 2 months prior to diagnosis should be notified, evaluated for urethritis, and offered empiric treatment.
- Repeat NAAT 3–6 months after completion of therapy.
Sexual partners should be treated simultaneously to avoid reinfection!